STOCK TITAN

Surrozen expects about $60M gross from stock offering

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Surrozen, Inc. (SRZN) entered into an underwriting agreement for the company’s sale of 1,894,540 shares of common stock at $31.67 per share. All shares in the offering are being sold by the company. Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. are the underwriters.

Gross proceeds are expected to be approximately $60 million before underwriting discounts and commissions and other offering expenses payable by the company. The offering is expected to close on November 16, 2026, subject to customary closing conditions. Chief Financial Officer Andrew Maleki signed on behalf of Surrozen.

Filing Explained

The company’s agreed share sale remains subject to customary closing conditions; if completed, issuing the shares would increase the share count and reduce existing holders’ percentage ownership.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Offering shares 1,894,540 shares All shares in the offering are being sold by Surrozen.
Offering price $31.67 per share Price for the common stock shares in the offering.
Expected gross proceeds approximately $60 million Before underwriting discounts and commissions and other offering expenses payable by Surrozen.
underwriting agreement financial
"entered into an underwriting agreement"
An underwriting agreement is a contract where a company selling new stocks or bonds hires financial firms to buy those securities and resell them to investors. It matters because the agreement sets the offering price, number of securities, fees and which party bears the risk if sales fall short—think of it as a promise that the sale will happen and a roadmap investors can use to understand how the new securities reach the market.
registration statement regulatory
"effective registration statement on Form S-3"
A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.
underwriting discounts and commissions financial
"before deducting underwriting discounts and commissions"
Underwriting discounts and commissions are fees paid to financial institutions that help sell new securities to investors. They act like a commission for their role in connecting companies with buyers, often reducing the amount of money the issuing company raises. For investors, understanding these costs helps gauge how much of their investment is going toward the actual securities versus fees paid to middlemen.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares is Surrozen (SRZN) selling, and at what price?

Surrozen is selling 1,894,540 shares of common stock at $31.67 per share. All shares in the offering are being sold by the company.

How much in gross proceeds does Surrozen (SRZN) expect from the share offering?

Surrozen expects approximately $60 million in gross proceeds before underwriting discounts and commissions and other offering expenses payable by the company.

When is Surrozen’s (SRZN) offering expected to close?

The offering is expected to close on November 16, 2026, subject to the satisfaction of customary closing conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001824893falseSurrozen, Inc./DENONE00018248932026-11-132026-11-13

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2026

 

 

Surrozen, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39635

30-1374889

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

171 Oyster Point Blvd

Suite 400

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 489-9000

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

SRZN

 

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Item 1.01 Entry into a Material Definitive Agreement.

On November 13, 2026, Surrozen, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 1,894,540 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at an offering price of $31.67 per share. All of the Shares in the Offering are being sold by the Company.

The gross proceeds from the Offering are expected to be approximately $60 million before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The Offering is expected to close on November 16, 2026, subject to the satisfaction of customary closing conditions.

The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by such parties.

The Offering is being made pursuant to the Company’s effective registration statement on Form S-3 (File No. 333-294542) (the “Registration Statement”) and a related prospectus and prospectus supplement to be filed with the Securities and Exchange Commission.

The foregoing description of the terms of the Underwriting Agreement do not purport to be complete and is qualified in its entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 hereto and is incorporated herein by reference.

A copy of the opinion of Cooley LLP relating to the validity of the Shares is filed as Exhibit 5.1 hereto and is incorporated by reference into the Registration Statement.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

 

 

 

 

Exhibit No.

 

Description

 

 

 

1.1

 

Underwriting Agreement, dated as of November 13, 2026, between Surrozen, Inc. and the Underwriters

5.1

 

Opinion of Cooley LLP

23.1

 

Consent of Cooley LLP (included in Exhibit 5.1)

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

SURROZEN, INC.

 

 

 

 

Date:

November 16, 2026

By:

/s/ Andrew Maleki

 

 

 

Name: Andrew Maleki
Title: Chief Financial Officer

 


Filing Exhibits & Attachments

3 documents

Keep reading